Insider Trading activities at Solis Pharma Us, Inc. (NONE)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Solis Pharma Us, Inc. (NONE) since 2013 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Solis Pharma Us, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1559060.

Total stock buying since 2013: $0.
Total stock sales since 2013: $28,812,008,820.
Total stock option exercises since 2013: $0.

▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies


4 insiders reported insider trading activities at Solis Pharma Us, Inc. (NONE):
Insider trading activities of Tiber Creek Corp
Insider trading activities of Mckillop James K
Insider trading activities of Cassidy James M
Insider trading activities of Mb Americus Llc

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Solis Pharma Us, Inc. (NONE).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2013 0 $0 29,400,009 $28,812,008,820 0 $0

Table 2. Monthly summary of insider trading at Solis Pharma Us, Inc. (NONE).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2013-09 0 $0 29,400,009 $28,812,008,820 0 $0

Table 3. Detailed insider trading at Solis Pharma Us, Inc. (NONE)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2013-09-30 Mb Americus Llc (Other) Sale 9 980.00 8,820
2013-09-30 Mckillop James K (Other) Sale 9,800,000 980.00 9,604,000,000
2013-09-30 Tiber Creek Corp (Other) Sale 9,800,000 980.00 9,604,000,000
2013-09-30 Cassidy James M (Other) Sale 9,800,000 980.00 9,604,000,000

Insider trading activities including stock purchases, stock sales, and option exercises of NONE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Solis Pharma Us, Inc. (symbol NONE, CIK number 1559060) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.